Entry Type
Name
Value
Parent Entry
Pharmacology Data Field
32-44 h (oral administration)
Medroxyprogesterone Acetate (API)
Pharmacology Data Field
Most metabolites excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates. Detectable amounts have been found in milk.
Medroxyprogesterone Acetate (API)
Pharmacology Data Field
2-4 h
Medroxyprogesterone Acetate (API)
Toxicology Data Field
There is sufficient evidence in experimental animals for carcinogenicity of MPA.
Medroxyprogesterone Acetate (API)
Pharmacology Data Field
- Competitive inhibitor of 3β-hydroxysteroid dehydrogenase/Δ5-4 isomerase II (3β-HSDII), which is essential for the biosynthesis of sex steroids and corticosteroids.
- CYP3A4: substrate,
inducer
- CYP2C8, CYP2C9:
inhibitor
Medroxyprogesterone Acetate (API)
Pharmacology Data Field
Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens.
Medroxyprogesterone Acetate (API)